We are live on
!
Find out more
PGM
Parian Global Management Portfolio holdings
AUM
$30.8M
1-Year Est. Return
51.25%
This Fund
S&P 500
This Quarter
Est. Return
-35.64%
1 Year Est. Return
-51.25%
3 Year Est. Return
+65.19%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$21.8M
AUM Growth
-$26.7M
(-55%)
Cap. Flow
-$1.9M
Cap. Flow
% of AUM
-8.7%
Top 10 Holdings %
Top 10 Hldgs %
92.11%
Holding
13
New
1
Increased
3
Reduced
8
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iRhythm Holdings
IRTC
|
+$1.21M |
| 2 |
Natera
NTRA
|
+$829K |
| 3 |
Stereotaxis
STXS
|
+$281K |
| 4 |
VAPO
Vapotherm, Inc. Common Stock
VAPO
|
+$185K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
The Oncology Institute
TOI
|
+$1.9M |
| 2 |
Neuronetics
STIM
|
+$691K |
| 3 |
ADMA Biologics
ADMA
|
+$576K |
| 4 |
Sera Prognostics
SERA
|
+$402K |
| 5 |
Alphatec Holdings
ATEC
|
+$360K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
VAPO
1
DELISTED
Vapotherm, Inc. Common Stock
VAPO
| $3.46M | 15.85% |
171,072
+5,058
| +3% | +$185K |
|
2
CVRx
CVRX
$130M
| $3.19M | 14.6% |
530,448
-9,825
| -2% | -$56.5K |
|
|
APEN
3
DELISTED
Apollo Endosurgery, Inc.
APEN
| $2.67M | 12.25% |
732,966
-6,199
| -0.8% | -$29.3K |
|
|
4
Neuronetics
STIM
$131M
| $2.3M | 10.55% |
717,973
-238,026
| -25% | -$691K |
|
|
CELL
5
DELISTED
PhenomeX Inc. Common Stock
CELL
| $1.9M | 8.68% |
381,496
-17,906
| -4% | -$93.8K |
|
|
6
iRhythm Holdings
IRTC
$3.54B
| $1.84M | 8.43% |
17,044
+9,146
| +116% | +$1.21M |
|
|
7
Stereotaxis
STXS
$140M
| $1.33M | 6.11% |
724,924
+117,655
| +19% | +$281K |
|
|
8
Alphatec Holdings
ATEC
$1.26B
| $1.27M | 5.8% |
193,822
-39,042
| -17% | -$360K |
|
|
9
Sera Prognostics
SERA
$85M
| $1.18M | 5.41% |
719,986
-209,087
| -23% | -$402K |
|
|
RNLX
10
DELISTED
Renalytix plc American Depositary Shares
RNLX
| $970K | 4.44% |
395,882
-63,579
| -14% | -$302K |
|
|
11
The Oncology Institute
TOI
$507M
| $930K | 4.26% |
183,828
-260,416
| -59% | -$1.9M |
|
|
12
Natera
NTRA
$37.9B
| $794K | 3.64% |
+22,402
| New | +$829K |
|
|
13
ADMA Biologics
ADMA
$1.94B
| – | – |
-315,000
| Closed | -$576K |
|
Similar funds
VCA
ACM
LUGPSI
KCM
SAM
SHI
FCOMV
KL
Parian Global Management's Q2 2022 Portfolio in Review
As of Q2 2022, Parian Global Management held 13 positions worth $21.8M, down 55% from $48.5M the previous quarter. Its ten largest holdings account for 92% of the portfolio.
Parian Global Management withdrew a net $1.9M in Q2 2022, closing 1 position and reducing 8 holdings. Its most notable exit was ADMA Biologics, an estimated $576K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Parian Global Management opened a new position in Natera worth $794K.
- Parian Global Management's largest Q2 2022 buy was Natera: 22,402 shares worth $794K.
- Parian Global Management added most to iRhythm Holdings in Q2 2022, an estimated $1.21M increase.
- Parian Global Management's biggest Q2 2022 reduction was The Oncology Institute, cutting an estimated $1.9M.
- Parian Global Management fully exited ADMA Biologics in Q2 2022, selling an estimated $576K.
- Parian Global Management's ten largest holdings make up 92% of its $21.8M portfolio in Q2 2022.
- Parian Global Management opened 1 new position and closed 1 in Q2 2022.
- Parian Global Management's portfolio value fell 55% quarter-over-quarter to $21.8M.
Based on Parian Global Management's 13F filing for Q2 2022, filed 15 Aug 2022.